Introduction

Multiple myeloma (MM) is a clonal B cell neoplasm, which involves terminally differentiated B cells (ie plasma cells).
There is increasing evidence for a multistep transformation process in the pathogenesis of MM, 1 with cell cycle regulation playing a central role, not only in the biological process, but also in the outcome of the disease. 2, 3 Recently, cell cycle regulators have been found to be a source of oncogenic events in many human tumors. 4 Those cell cycle regulators involved in primary tumors act in the transition from the G1 to S phases. [4] [5] [6] These include the D-type cyclins 1, 2 and 3 and their respective cyclin-dependent kinases (CDKs) 4 and 6. Cyclins bind to and activate the CDKs, which leads to phosphorylation of the tumor suppressor protein Rb, just before the S phase. 7 A newly identified family of functionally related proteins termed cyclin-dependent kinase inhibitors (CDKIs) play a critical role in the inactivation of CDKs activity. 8 These include p21, p27, p28, p16, p15 and p18. CDKIs compete with cyclin D for binding to CDK4/CDK6 and, therefore, inhibit CDK4/6 complex kinase activity. 9, 10 One of the most important CDKIs is the p16 protein, which negatively regulates cell proliferation and acts as a suppressor protein. The p16/INK4a gene is mapped to the 9p21, a region frequently altered in several types of tumors. 9, 11 The human p16 gene is complex, with two partially overlapping transcripts with distinct coding potential, produced from separate promoters. Thus, two transcripts of the p16 gene are described. They are identical in exon 2 (E2) and exon 3 (E3), but they contain a different exon 1 (E1), termed E1␣ and E1␤. 12 Inactivation of p16 gene can be caused by point mutations, homozygous deletions, hemyzygous deletions with point mutations at the remaining allele, and methylation of the gene. 13 These mechanisms of inactivation of the p16 gene have been found in cell lines derived from a variety of human cancers, 11, 14 and in both solid tumor 15 and hematological malignancies. 16 Thus, frequent homozygous deletion of the p16 gene has been reported in T (50-75%) acute lymphoblastic leukemia (ALL), in B-ALL (15-20%) and adult T cell leukemia/lymphoma (35%); [17] [18] [19] in non-Hodgkin's lymphoma (NHL), the incidence is lower (5-30%), mainly affecting primary large cell NHL and transformed and aggressive variants of NHL. 16, [20] [21] [22] Moreover, the presence of homozygous deletions of the p16 gene is associated with poor prognosis in ALL 23 and NHL. 22 Inactivation of the p16 gene by point mutations is less frequent in hematological malignancies, and has only been occasionally reported in childhood T-ALL. 24 Recently, de novo methylation of a 5Ј CpG island into exon E1␣ of p16 gene has been observed. 13 This methylation is associated with transcriptional silencing of the p16 gene and has been described in cell lines [25] [26] [27] [28] and primary tumors, such as NHL, [29] [30] [31] and solid tumors. 25, 26, 32 p16 was thought to play a marginal role in the pathogenesis of MM, since a low frequency of gene deletions was reported (6%) and no point mutations were observed. 33 However, two recent studies have reported a high prevalence of methylation in the exon E1␣ of the p16 gene (50-75%), 27, 34 but these two studies included a small number of cases (12 and 16 cases, respectively). Therefore, these results should be considered as preliminary. In this study, we have analyzed the methylation pattern of exon E1␣ of the p16 gene in a group of 101 untreated MM patients and five primary plasma cell leukemia (PCL) by PCR methylation assay, confirmed by Southern blot.
Materials and methods
Patients and samples
One hundred and one patients with untreated MM and five primary PCL were included in this study. The diagnosis was made according to the criteria of the Chronic Leukemia Myeloma Task Force 35 and staging was made following the Durie and Salmon criteria. 36 All studies were carried out in bone marrow samples at diagnosis, containing a variable number of plasma cells (5-80%) identified by immunophenotype, based on the plasma cell reactivity for the CD38 (Leu17; Becton Dickinson, San José, CA, USA) and CD138 (Imico, Madrid, Spain), monoclonal antibodies previously described. 37, 38 As normal controls, we used bone marrow samples obtained from healthy donors. In all samples, the gen-omic DNA was isolated by standard proteinase K digestion, phenol and chloroform extraction and ethanol precipitation. 39 
PCR-based methylation assay
A PCR assay relying on the inability of some restriction enzymes (EagI, SacII) to digest methylated sequences was used to analyze the methylation status of the first exon (E1␣) of the p16 gene. 31, 40 Two g of genomic DNA were digested by 40 units of the enzyme EagI (New England Biolabs, Beverly, MA, USA), overnight. This methylation-sensitive enzyme has one restriction site inside exon E1␣. Digested DNA (250 ng) was subject to PCR amplification of p16 exon E1␣ and exon E2. Exon E2 was used as an internal control since exon E2 does not have any EagI restriction site. Genomic DNA from healthy donors was used as a control to test that normal cells were non-methylated in this region and that the methylation-sensitive enzyme had cut the exon E1␣ in these samples. In addition, we also used undigested DNA from these samples for the amplification of exon E1␣ and exon E2. Primers used for the amplification of p16 exon E1␣ and exon E2 have been previously described (Table 1) .
14 PCR conditions were as follows: 94°C for 5 min, five cycles of 94°C for 30 s, 68°C for 30 s, and 72°C for 1 min, followed by 25 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 1 min, using a Perkin-Elmer thermal cycler (Gene Amp PCR System 2400; Perkin-Elmer, Foster City, CA, USA). PCR products were electrophoresed on 2-3% agarose gels. To rule out the possibility of incomplete restriction, all samples which experienced amplification of exon E1␣ were tested at least twice to ensure reproducibility of the results.
Southern blot hybridization
To confirm the methylation status of the p16 exon E1␣ CpG island, samples were also analyzed by Southern blot analysis. Five g of genomic DNA was restricted with 45 units of HindIII (New England Biolabs) and 40 units of SacII or EagI enzymes (New England Biolabs), overnight. After restriction, the samples were electrophoresed in a 1% agarose gel, and then transferred on to a nylon membrane. Filters were then hybridized with a probe for the exon E1␣ of the p16 gene that was amplified by the primers used for PCR-based analysis, and labeled with 32 P. 39 After overnight hybridization, filters were washed stringently and exposed to X-ray film. The expected fragment sizes recognized by this probe when the genomic DNA is digested with the restriction enzymes utilized are rep- Table 1 Primer sequences for PCR amplification of the p16 gene. E1 is exon 1 and E2 is exon 2 of the p16 gene Figure 1 . Southern blot analysis was used to confirm the methylation status in 20 random samples that had experienced amplification of the exon E1␣ by PCR-based methylation and 20 random samples with non-methylation of the exon E1␣.
Results
Patient characteristics
In the group of 106 patients studied, the male to female relation (M:F) was 2:1 and the median age was 65 years (range 
Methylation status of the exon E1␣ of the p16 gene by PCR
Since the methylation-sensitive enzymes cut the exon E1␣ of the p16 gene when it is non-methylated, only the samples with hypermethylation of exon E1␣ experienced amplification. Exon E1␣ of the p16 gene was amplified, showing the expected 349 bp band, in 41/101 MM patients (40.5%), as well as in four of the five (80%) patients with primary PCL. Exon E2 was amplified in all samples (including methylated and non-methylated), showing a 510 bp band, thus confirming a correct PCR development. In our series, 35 methylated cases displayed a high intensity band, but there were 10 cases with a weak methylated band. Four of them had less than 10% bone marrow infiltrating plasma cells, while the remaining six cases had a higher infiltration. Thus, a low intensity of the methylated band could be attributed either to the presence of a low number of bone marrow infiltrating plasma cells, or to a partial rather than a complete methylation (Figure 2 ).
Methylation status of the p16 gene by Southern blot
The methylation status of exon E1␣ by Southern blot was analyzed at the SacII and EagI sites. Of the 20 cases used as 'positive samples' (as they had experienced methylation of the exon E1␣ by PCR) the methylation status by Southern blot was confirmed in 18 ( Figure 3 ). In these 18 cases, a 6 kb band from the methylated cells was observed; four of them, with Ͼ75% bone marrow infiltrating plasma cells, showed this band alone, while in the remaining 14 cases, a 6 kb band appeared together with 2.1 kb and 0.5 kb bands (from EagI digestion), or 3.9 kb and 0.3 kb bands (from SacII digestion) originated from the residual normal cells present in the sample. The two cases that did not show a 6 kb band after digestion with HindIII and SacII showed small fragments of 3.9 kb and 0.3 kb bands, despite the fact that they had experienced amplification of the exon E1␣ by PCR after EagI digestion. These two discrepant cases could be explained by the low plasma cell infiltration in bone marrow (Ͻ10%) observed in one case and by suboptimal DNA quality for the Southern blot analysis in the second case. On the other hand, none of 20
Figure 2
Methylation pattern of the exon E1 of the p16 gene in MM patients analyzed by PCR. Products of the exon E1 and E2 are shown on the top and bottom of the figure, respectively. The amplification of exon E1 after digestion with EagI indicates that this restriction site was methylated and the amplification of the exon E2 of the p16 gene indicates acceptable PCR development. Lane 1: marker DNA digested with HindIII. Lane 2: DNA from a healthy donor, digested with EagI. Lane 7: undigested DNA from the same healthy donor. Lane 8: distilled water. The presence of a band corresponding to the exon 1 of the p16 gene in lanes 6 and 7 represents methylated samples.
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Figure 3
Methylation status at 5Ј CpG island of the p16 gene by Southern blot. Sizes of fragments, in kb, are specified on the left. Cases were digested using HindIII and SacII enzymes, and hybridized with the exon E1 probe. Lane 1: DNA sample from a healthy donor digested only with HindIII, which originates a 6 kb fragment. Lane 2: the same DNA sample digested with both enzymes, originating a 3.9 kb fragment (unmethylated sample). Lanes 3-11: DNA from MM cases digested with the HindIII and SacII restriction enzymes. Lanes 3, 5 and 6 only show the 3.9 kb band, thus indicating that they are unmethylated cases. Lanes 4, 8 and 11 show the presence of the 6 kb band alone, indicating that they are methylated cases with a high plasma cell infiltration. Lanes 7, 9 and 10 show the presence of both 6 and 3.9 kb bands, thus indicating the presence of methylated cells accompanied by residual normal cells. In these last cases, the 6 kb band is originated from methylated neoplastic plasma cells, while the 3.9 kb band derives from the unmethylated normal cells. samples used as 'negative cases' (non-methylated by PCR) displayed a 6 kb band (Figure 3) .
Discussion
In the present study, we have analyzed by PCR and Southern blot analysis the methylation status of the p16 gene in 101 untreated MM patients and five primary PCL. A high frequency of methylated p16 gene (40.5%) was found in MM patients, increasing up to 80% in primary PCL patients. The majority of inactivating alterations of the p16/INK4a gene in hematological malignancies are homozygous deletions rather than point mutations. 4, 18 However, in MM, p16/INK4a gene deletions are infrequent (6% of cases) and no point mutations have been found. 33 This led us to believe that p16 gene was not critical in the pathogenesis of MM. Recent data suggest that hypermethylation of the CpG island of the exon E1␣ of the p16 gene may be another mechanism of inactivation in solid tumors and hematological malignancies.
14, 16, 25, 26 Preliminary results suggest that this mechanism may be involved in the pathogenesis of an elevated number of MM patients. Ng et al, 34 in a series of 12 MM patients, including treated and untreated cases with plasma cell infiltration of bone marrow Ͼ50%, reported an incidence of hypermethylation of the p16 gene of 75%; Tasaka et al 27 have found that eight out of 16 untreated MM patients (50%) are hypermethylated at exon E1␣ of the p16 gene. Our results, in a large series of 106 untreated patients, confirm the possible pathogenic role of the p16 gene in the development of MM. Thus, we have found that 40.5% of MM patients and 80% cases of PCL, had hypermethylation of the exon E1␣ of p16 gene by PCR and Southern blot analysis. It is very difficult to know the exact sensitivity of the PCR-based methylation assay. After digestion of DNA with the methylation-sensitive restriction enzyme EagI, PCR will amplify from primers flanking the restriction site only if DNA cleavage has been prevented by methylation. Moreover, the restriction of unmethylated DNA must be complete, since any uncleaved DNA will be amplified by PCR yielding a false positive result for methylation, since there are no differences between methylated samples and incompletely restricted samples (all will experience amplification of the exon 1␣ of the p16 gene). If we make studies of sensitivity with DNA samples from healthy donors, we can obtain high sensitivity; in our hands it is 10 −3 . However, we cannot ensure whether the result is true or a false positive. So, to rule out the possibility of incomplete restriction, all samples which experienced amplification of exon E1␣ were tested at least twice to ensure reproducibility of the results. Furthermore, Southern blot hybridization was made to confirm the methylation status using another restriction enzyme (SacII). In this way, we can ensure that the methylated samples are methylated and this is not a false positive result. Urashima et al 28 studied the methylation status of the p16 gene in B cells obtained from spleen and cultured and they were not methylated. The good correlation between the PCR and Southern blot assay for methylation detection of the p16 gene directs that the assay is specific. Alterations in methylation of the CpG island of the p16 gene are intimately associated with regulating the expression of the gene. 43 Recently, Signal and Ginder 44 reviewed DNA methylation and explained the different mechanisms of DNA methylation and transcriptional repression. This was confirmed by Tasaka et al, 27 who examined the expression of the p16 gene by RT-PCR in MM cell lines and confirmed the absence of expression when it is methylated and by Urashima et al, 28 who studied the expression of the p16 protein by immunoprecipitation and Western immunoblotting in MMderived cell lines, patient PCL and MM cells and showed a good correlation between methylation and no expression of the p16 protein (cell lines and patient PCL cells) and no methylation and expression of the p16 protein (patient MM cells and B cell normal preparation). This cannot be assessed in our samples, since the presence of the p16 transcript could be attributed to contamination by normal cells in the sample or to plasma cells with a partial methylation pattern. Cell sorting technologies based on CD38 expression might be helpful (used by Urashima et al 28 ), but this is a retrospective study, and we do not have any samples to validate our methylation data. Data reported here support the notion that the methylation must be complete in the majority of methylated cases, since the intensity of the methylated band was usually proportional to the plasma cell infiltration. Accordingly, the four cases with a weak methylated band could be justified by the existence of a low number of infiltrating plasma cells (Ͻ10%). However, there were six other cases in which the methylated bands were weak although they had a relatively high infiltration of plasma cells (median value 21.4; standard deviation 9.8). Thus, partial methylation could be implicated as a mechanism affecting the p16 gene in MM. These data are in accordance with those published by Jones, 45 who showed that the density and extent of the methylation can vary according to the development stage of the specific tumor, and that the level of transcriptional repression is dependent on the methylation density.
Our findings confirm that methylation of the p16 gene is a frequent event in MM at diagnosis, and this is probably associated with hampered cell cycle suppression. Interestingly, four of five primary PCL cases studied showed a methylated p16 gene. In a recent report, we have shown that primary PCL has a very high percentage of plasma cells in S-phase, 42 which could be explained by the inactivation of the p16 function, via p16 gene methylation. This finding could help to support a prognostic role for p16 gene in MM, as has been described in other hematological malignancies, such as ALL 23 and NHL. 22 The number of patients included in this group is very small. In a further analysis, we will study other monoclonal gammopathies to identify the exact correlation.
In summary, our study confirms that, even at diagnosis, hypermethylation of the p16 gene is a very frequent event in MM. Large prospective studies are required in order to evaluate whether or not this observation is a major event in MM, with clinical and biological implications, or whether it is only an additional finding marginally associated with the disease outcome.
